Bonesupport Holding ABBOEUF 77 Return-on-Tangible-Asset is 20.07% as of Mar. 2026. GuruFocus rates BOEUF with a GF Score™ of 77/100 and a GF Value™ of $42.63 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Bonesupport Holding AB ranks better than 94.96% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bonesupport Holding AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $22.9 Mil. Bonesupport Holding AB's average total tangible assets for the quarter that ended in Mar. 2026 was $114.2 Mil. Therefore, Bonesupport Holding AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 20.07%.
The historical rank and industry rank for Bonesupport Holding AB's Return-on-Tangible-Asset or its related term are showing as below:
BOEUF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -75.72 Med: -26.52 Max: 47.12
Current: 18.73
During the past 12 years, Bonesupport Holding AB's highest Return-on-Tangible-Asset was 47.12%. The lowest was -75.72%. And the median was -26.52%.
BOEUF's Return-on-Tangible-Asset is ranked better than 94.96% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.595
vs BOEUF: 18.73
Bonesupport Holding AB (OTCPK:BOEUF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bonesupport Holding AB Return-on-Tangible-Asset Related Terms
Bonesupport Holding AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bonesupport Holding AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonesupport Holding AB Return-on-Tangible-Asset Chart
BOEUF vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Bonesupport Holding AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonesupport Holding AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonesupport Holding AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bonesupport Holding AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 20.07% mean?
Bonesupport Holding AB (BOEUF) has a Return-on-Tangible-Asset of 20.07% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bonesupport Holding AB and its competitors. According to the industry distribution chart, Bonesupport Holding AB ranks #43 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 5%.
Is Bonesupport Holding AB's Return-on-Tangible-Asset too high?
Bonesupport Holding AB's current Return-on-Tangible-Asset is 20.07%. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.60. Bonesupport Holding AB's value of 20.07% is 3273.1% above this industry median. Based on the distribution chart, Bonesupport Holding AB ranks #43 out of 854 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bonesupport Holding AB has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bonesupport Holding AB's Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonesupport Holding AB ranks #43 out of 854 companies for Return-on-Tangible-Asset. This places Bonesupport Holding AB in the top 5% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.60. Bonesupport Holding AB's value of 20.07% is 3273.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.60, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bonesupport Holding AB's current Return-on-Tangible-Asset of 20.07% is 3273.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bonesupport Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonesupport Holding AB's current Return-on-Tangible-Asset is 20.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonesupport Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Bonesupport Holding AB (BOEUF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.63, compared to a current price of $21.40 — trading 49.8% below its estimated fair value. The current Return-on-Tangible-Asset is 20.07% and 3273.1% above the Medical Devices & Instruments industry median of 0.60. Bonesupport Holding AB's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bonesupport Holding AB (BOEUF), the current Return-on-Tangible-Asset is 20.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonesupport Holding AB (BOEUF) Overvalued in 2026?
Based on GuruFocus' analysis, Bonesupport Holding AB stock appears to be undervalued.
The current stock price of $21.40 is trading 49.8% below its estimated GF Value™ of $42.63.
GuruFocus considers Bonesupport Holding AB to be Significantly Undervalued.
Key valuation signals for BOEUF:
Return-on-Tangible-Asset: 20.07%
GF Value™: $42.63 vs. price of $21.40 (49.8% below fair value)
Industry Position: 3273.1% above the Medical Devices & Instruments median (#43 of 854)
No single metric tells the full story. See the BOEUF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonesupport Holding AB is a fast-growing ortho-biologics company that focuses on the treatment of bone disorders. The Company develops and commercializes injectable bio-ceramic bone graft substitutes based on its CERAMENT platform, which remodels to bone and can release pharmaceuticals to promote healing. The products of the company focus on trauma, revision arthroplasty (replacement of joint prostheses), chronic osteomyelitis (bone infection), and foot and ankle surgery. The Group manages and monitors operations in two operating segments: United States and Europe & Rest of the World (EUROW).
77GF Score
Get the complete analysis for BOEUF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOEUF has been successfully added to your 
